Mcl-1 is an antiapoptotic member of the Bcl-2 family that can promote cell viability. We report here that Mcl-1 is a new substrate for caspases during induction of apoptosis. 
Introduction
Myeloid cell leukemia-1 (Mcl-1) was originally identified as a gene upregulated early in the differentiation program of the human myeloid leukemia cell line, ML-1 (Kozopas et al., 1993) . Mcl-1 promotes cell viability as do Bcl-2, Bcl-X, and other antiapoptotic members of this family (Reynolds et al., 1996; Zou et al., 1999; Cory and Adams, 2002) . The expression of Mcl-1 appears to be related to the programming of differentiation/development and cell viability/death, and recent data suggest that Mcl-1 may function by providing short-term enhancement of cell viability (Craig, 2002) . This is of particular importance in myeloid cells initiating differentiation in response to phorbol esters and in neutrophils undergoing spontaneous apoptosis. Mcl-1 deficiency results in periimplantation lethality and it was very recently reported that mice conditional for Mcl-1 display a profound alteration of lymphoid development (Rinkenberger et al., 2000; Opferman et al., 2003) .
Mcl-1 shows sequence similarity, particularly in the carboxyl portion, to Bcl-2 (Kozopas et al., 1993) . It is however distinct from Bcl-2 and Bcl-xL in that it lacks a true BH4 domain and is a larger protein that encodes an additional internal PEST domain. Mcl-1 is regulated at the transcriptional, post-transcriptional and translational levels. Induction by phorbol esters in hematopoietic cell lines involved active transcription (Yang et al., 1996; Townsend et al., 1999; Herrant et al., 2002) , which is stimulated through the Erk1/2-mediated pathway (Townsend et al., 1998) . In other cell systems, the Erk1/2, the p38MAPK, the PI3K/AKT or the JAK/ STAT pathways are also involved in Mcl-1 expression (Craig, 2002) . Mcl-1 can also be regulated at the posttranscriptional level by alternative splicing (Bae et al., 2000) . While full-length Mcl-1 consists of three coding exons, a splice variant, Mcl-1 S arises by the juxtaposition of exons 1 and 3. Full-length Mcl-1 contains the BH1-BH4 Bcl-2 homology domains while Mcl-1 S contains only the BH3 domain. Accordingly as its BH3-only counterparts Mcl-1 S induces cell death rather than promoting cell survival (Bingle et al., 2000) . Thus, Mcl-1 can be converted by alternative splicing from an anti to a proapoptotic gene product, as it is the case for Bcl-X L (Boise et al., 1993) .
Finally, Mcl-1 is also modulated post-translationally by phosphorylation (Domina et al., 2000; Jourdan et al., 2000; Inoshita et al., 2002) . Two main pathways of Mcl-1 phosphorylation have been reported to date. The first one is stimulated by phorbol esters through Erk1/2 activation and the second one by agents that cause cells to accumulate in the G2/M phase of the cell cycle including colchicine, taxol and okadaic acid. Only this later pathway results in a subsequent electrophoretic mobility shift. A fundamental difference between these two pathways is that phorbol ester-induced phosphorylation occurs in viable cells while the taxol and okadaic acid-dependent phosphorylation takes place in cells that are undergoing apoptosis.
Mcl-1 also appears to be rapidly modulated by degradation but whether or not the putative PEST sequence present in the N-terminal part of the molecule is involved in this process is still a matter of debate (Kozopas et al., 1993; Akgul et al., 2000; Breitschopf et al., 2000) . Nevertheless, the conclusion emerging from these observations is that Mcl-1 is a highly regulated protein, suggesting that the ability to closely control Mcl-1 gene expression and protein level is critical for the fine tuning of cell fate decisions, more particularly cell death and survival, but also differentiation.
The findings presented in this manuscript describe a new post-translational mechanism for the regulation of Mcl-1 that involves caspase-dependent cleavage. The resulting proteins that contain the BH1-BH3 domains of Bcl-2 family members have an altered antiapoptotic potential but exhibit an increased association with Bim. We concluded that the cleavage of Mcl-1 by caspases during apoptosis generated a dominant-negative molecule with increased affinity for Bim.
Results
Cleavage of Mcl-1 during induction of apoptosis in different cell lines CH11 induced the rapid cleavage of Mcl-1 in JA3 (Jurkat) cells, which was detectable as soon as 2 h after antibody addition (Figure 1Aa ). Interestingly, Mcl-1 was cleaved in several cell lines under various stimuli (Figures 1Ab-d) . Mcl-1 cleavage was noticeably observed 4-8 h following induction of apoptosis by staurosporine or actinomycin D in HeLa cells (Figure 1Ab ), 18 h after B cell receptor engagement in the immature Ramos B cell line ( Figure 1Ac ) and 36 h after treatment of the chronic myelogenous leukemia cell line K562 by the Bcr-Abl inhibitor imatinib mesylate (Figure 1Ad ). In each case the cleavage of Mcl-1 generated a 24 kDa fragment and was shown to parallel that of Poly-ADP-Ribose-Polymerase (PARP). Interestingly, Mcl-1 cleavage was also detected in primary cells such as thymocytes ( Figure 1B ) and neutrophiles (not shown). When incubated for 4 h at 371C, mouse thymocytes undergo an apoptotic program that is characterized by DNA fragmentation (Figure  1Ba ), caspase activation ( Figure 1Bb ) and Mcl-1 cleavage (Figure 1Bc ). Mouse thymocytes were shown to express the short form of Mcl-1 (Mcl-1 S ). Mcl-1 S transcript arised from an alternative splicing that generated an Mcl-1 protein truncated from the middle part of the molecule (Bae et al., 2000) . The corresponding 24 kDa short form of Mcl-1 appears to retain the caspase cleavage site(s) since it gave rise to a 17 kDa fragment in thymocytes undergoing apoptosis (Figure 1Bc ).
Mcl-1 cleavage is caspase dependent
Preincubation of JA3, HeLa, Ramos and K562 cells with the pancaspase inhibitor Z-VAD-fmk abolished the generation of the 24 kDa Mcl-1 fragment following CH11, staurosporine, anti-IgM or imatinib mesylate stimulation, respectively (Figure 2A ), strongly suggesting that caspases are responsible for the Mcl-1 cleavage in apoptotic cells. We have previously shown that Mcl-1 is a substrate for recombinant caspases in vitro, and identified a major Mcl-1 cleavage product as a 24 kDa fragment (Herrant et al., 2002) . To analyse more precisely the cleavage of Mcl-1, in vitro transcribed and translated
35
S-labelled Mcl-1 was incubated at 371C with either purified recombinant caspases or cellular extracts prepared from Fas-stimulated JA3 cells ( Figure  2Ba ). The proteolytic profile obtained with recombinant caspases 3, 6 or 7 was indistinguishable from that induced by a cellular extract prepared from Fasstimulated JA3 cells. Finally, cleavage of Mcl-1 was abolished in the presence of the caspase inhibitors Z-VAD-fmk (not shown) and Ac-DEVD-CHO (Figure 2Bb ).
Identification of the caspase cleavage sites in Mcl-1
In view of the results described above, it appears that Mcl-1 is cleaved by caspases at least at two different sites. As the antibody used for the Western blot presented in Figure 1 recognizes the C-terminal domain of the protein, the 24 kDa product most likely corresponds to the C-terminus part of the protein. A careful examination of the Mcl-1 sequence allows us to identify two aspartate residues at position 127 and 157, located in the sequences EELD/G and TSTD/G, respectively, which could match with authentic caspase sites and are compatible with the generation of 24, 19, 17 and 12 kDa fragments. Notably, the EELD/G peptide was strictly conserved in Mcl-1 sequences from different mammals species (not shown).
To identify formally caspase sites in Mcl-1, we generated point mutations by replacing aspartate 127 (Mcl-1 A127D) or 157 (Mcl-1 A157D) by alanine individually and together in order to obtain the double mutation (Mcl-1 dm). We also realized deletion of the 127 (Mcl-1 D127) and 157 (Mcl-1 D157) N-terminal amino acids ( Figure 3A ). Mcl-1 wt, A127D, A157D, dm, D127 and D157 were next transcribed and translated in vitro in the presence of 35 S-methionine and incubated with recombinant caspase 3 in either the presence or absence of Ac-DEVD-CHO. As expected, Mcl-1 wt was proteolytically processed in four fragments of 24, 19, 17 and 12 kDa (Figure 3Ba ). Mutation of Asp127 was accompanied by the loss of the 24 and 12 kDa fragments (Figure 3Bb ), while mutation of Asp157 abrogated the generation of the 19 and 17 kDa fragments (Figure 3Bc) . Interestingly, the double-mutant was found to be totally resistant to caspase 3 cleavage (Figure 3Bd ). Identical results were obtained using recombinant caspases 6 and 7 (not shown). Deletion of the first 127 amino acids generated the 24 kDa fragment that was cleaved by recombinant caspase 3 after Asp157 in the expected 19 kDa fragment (Figure 3Be ). Finally, deletion of the first 157 amino acids gave rise to the 19 kDa fragment that was no more a substrate for recombinant caspases (Figure 3Bf ). In each case, Ac-DEVD-CHO was found to abolish Mcl-1 cleavage induced by recombinant caspase 3. On the whole, the experiment shown in Figure 3B allowed us to identify the two caspase cleavage sites present in Mcl-1 as Asp127 and Asp157. used five times more Mcl-1 than Bim-EL plasmids. In the first set of experiments, we looked for the cellular distribution of the different Mcl-1 proteins as compared to that of EGFP-Bim-EL. The use of an anti-myc-TRed antibody revealed that Mcl-1 wt was localized mainly near the internal face of the plasma membrane where it colocalized with a-Tubulin (Figures 5Aa and b) . In some cases, we were able to detect a modest association of Mcl-1 wt with Bim-EL (Figure 5Ac ). By contrast, Mcl-1 D127 coassociated closely both with EGFP-Bim-EL ( Figure 5Ad ) and Hexokinase-2, a mitochondrial marker (Figure 5Ae) .
Expression of Mcl-1 in HeLa cells
To confirm the confocal microscopy results we also performed coimmunoprecipitation experiments. Myctagged-Mcl-1 constructs were thus cotransfected or not with EGFP-Bim-EL in HeLa cells, as described above. Cellular extracts were then lysed and immunoprecipitated with an anti-Bim antibody before Western blotting with an anti-myc antibody. All the Mcl-1 forms were shown to interact with Bim-EL ( Figure 5B ), but a careful examination of Mcl-1 content in total extracts and after immunoprecipitation with anti-Bim antibodies 
Discussion
We and others have previously identified the cleavage of Mcl-1 in cells undergoing apoptosis (Herrant et al., 2002; Snowden et al., 2003) . The present study was thus conducted to better characterize this cleavage, to determine whether caspases participated in this process and finally to clarify its physiological role. We first demonstrated that Mcl-1 is a new substrate for caspases in a broad variety of cell lines and primary cells under a large panel of apoptotic stimuli. Cleavage of Mcl-1 generates four fragments of 24, 19, 17 and 12 kDa, both in intact cells and in vitro, and was inhibited by selective caspase inhibitors. Mutation experiments allowed us to determine that Mcl-1 was cleaved after Asp127 and Asp157, in the so-called PEST sequence present in the protein. As a consequence, the resulting protein that lacks the first 127 or 157 amino acids contains only the BH1-BH3 domains of Bcl-2 family members, and thus resembles proapoptotic proteins such as Bax. This observation is in keeping with previous results from Cheng et al. (1997) and Fujita et al. (1998) , showing that Bcl-2 and Bcl-X L are cleaved by caspase 3 in their Nterminal domains. Thus, cleavage of antiapoptotic Bcl-2 family members during apoptosis could be a more general mechanism than that previously expected. Nevertheless, Mcl-1 cleavage results in the loss of the putative BH4 homology domain that is supposed to be required for the antiapoptotic activity of all the Bcl-2 family members.
Interestingly, the main cleavage site in Mcl-1, that is, EELD/G is closely related to the cleavage sites EEED/ G, EERD/G, EEAD/A and EETD/L previously identified in Topoisomerase-1, p59-Fyn, Caspase-2 and SRF, respectively (Li et al., 1997; Earnshaw et al., 1999; Ricci et al., 1999; Bertolotto et al., 2000; Luciano et al., 2001 ). More interestingly the EELD/G site in Mcl-1 is remarkably conserved in several mammal species whereas it does exist as a significant variation in the second Mcl-1 caspase site (TSTD/G in the human protein), reinforcing the notion that EELD/G represents the physiological caspase cleavage site of the protein. Interestingly, we were unable to detect Bcl-2 cleavage in the different cell lines used in Figure 1 upon conditions where Mcl-1 was readily cleaved. The reasons for this lack of Bcl-2 cleavage are currently unknown, but Fujita et al. (1998) reached the same conclusion by comparing Bcl-2 and Bcl-X L cleavage in CTTL2 cells.
In the present study, we have also shown that deletion by caspase cleavage of the putative BH4 domain and of a part of the PEST sequence generated two Mcl-1 fragments that structurally resemble the proapoptotic protein Bax. Thus, it was tempting to speculate that Mcl-1 D127 and Mcl-1 D157 might kill cells by mechanisms similar to those used by Bax. In fact, despite numerous attempts, we were unable to demonstrate that the cleaved forms generated by caspase cleavage had by themselves a proapoptotic function.
Rather, our findings demonstrate that cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-ELinduced apoptosis.
Two Bcl-2 family members have been identified as privileged interactors in the regulation of apoptosis Mcl-1 and the BH3-only protein Bim (Han et al., 2004) . Bim activates Bax and Bak by directly occupying the pocket Bim. Accordingly, colocalization of Bim with Mcl-1 wt was a relatively rare event even though some coassociation can be detected by confocal microscopy ( Figure  5Ac ). By contrast, we found that high proportion (20-50%) of Mcl-1 D127 and Mcl-1 D157 (not shown) coimmunoprecipitates with Bim, suggesting that the Figure  5Ae ). Bim has been previously shown to be sequestered to the microtubular dynein complex in healthy cells (Puthalakath et al., 1999) . Thus, the colocalization of Bim on mitochondria observed in the present study could seem a priori unexpected but recent reports from the literature corroborate the constitutive association of Bim on mitochondria or internal membranes in T and B cells (Mouhamad et al., 2004; Zhu et al., 2004) . Finally, we found by confocal microscopy that Mcl-1 wt rather than Bim-EL colocalized with a-Tubulin.
Interestingly, it appears that the main characteristics of cleaved Mcl-1 are its very strong association with Bim-EL on the mitochondria as compared to Mcl-1 wt. In light of the present results, it is tempting to propose that the N-terminal domain of Mcl-1 may exert a negative constraint that interferes with its binding to Bim and that caspases by removing this constraint may favour interaction between Bim-EL and cleaved Mcl-1. (Inoshita et al., 2002) . Finally, a 25 amino acids stretch in the Nterminus of Mcl-1 has been shown to bind with Tankyrase-1, an interaction that could serve to downmodulate specifically this Bcl-2 family member (Bae et al., 2003) . It is worth mentioning that both phosphorylation events and Tankyrase-1 binding occurs in the domains of Mcl-1 that are deleted following caspase cleavage.
Mcl-1 was originally identified as a gene induced early by phorbol esters in the process of differentiation of ML1 myeloid leukemia cells (Kozopas et al., 1993) . Thus, one possible role of this protein is to function in the fine tuning of differentiation and death processes. Mcl-1 also promotes cell survival in neutrophils and in several hematopoietic malignancies such as multiple myeloma, CLL-B cells and Burkitt's lymphoma (Derenne et al., 2002; Pedersen et al., 2002; Zhang et al., 2002; Jourdan et al., 2003) . Noticeably, Mcl-1 is implicated in CLL survival and its overexpression in this disease is associated with pour prognosis (Kaufmann et al., 1998; Kitada et al., 1998) . It has been reported that CLL cells undergoing apoptosis show a rapid caspase-dependent cleavage of Mcl-1 (Snowden et al., 2003) . Thus, drugs that induced the caspase-dependent cleavage of Mcl-1 may be of potential interest in the treatment of CLL, but also in other hematopoietic malignancies such as multiple myeloma and some lymphoma in which cell survival is intimately linked to Mcl-1 expression (Puthier et al., 2001; Jourdan et al., 2003) .
Overall, the present findings demonstrate that caspase cleavage of Mcl-1 is a general mechanism during induction of apoptosis by various stimuli in different cell lines and primary cells. The two resultant fragments exhibit a much higher affinity for Bim than their uncleaved counterparts and are efficiently targeted to mitochondria. Thus, we proposed that cleavage of Mcl-1 by caspases may generate a dominant-negative molecule 
Materials and methods

Reagents and antibodies
Sodium fluoride, sodium orthovanadate, phenylmethylsulfonyl fluoride (PMSF), aprotinin, leupeptin, staurosporine and actinomycin D were purchased from Sigma (Saint-Louis, MO, USA). RNase A and proteinase K were from Roche Molecular Biochemicals (Indianopolis, IN, USA). Ac-DEVDpNA, Ac-DEVD-CHO and Z-VAD-fmk were from Alexis Biochemicals (Lausen, Switzerland). Imatinib mesylate was provided by Novartis Pharma (Basel, Switzerland). Anti-Fas monoclonal antibody (CH11) was from Euromedex (Souffelweyersheim, France) and anti-human IgM was from Jackson Immuno-Research Laboratories (Baltimore, PA, USA). Peroxidase-conjugated, anti-Hsp60, anti-Mcl-1, anti-Myc(9E10), anti-p56-Lck and anti-a-Tubulin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-PARP antibody was from Biomol (Plymouth Meeting, PA, USA). Anti-Hexokinase-2 was from Chemicon International (Temecula, CA, USA) and anti-Bim from Sigma. Antimouse and anti-goat antibodies were from Dakopatts (Glostrup, Denmark) and anti-rabbit antibody from Cell Signaling Technology (Beverly, MA, USA).
Cells
Jurkat T cells (clone JA3, a kind gift of Dr John Blenis; Harvard Medical School, Boston, MA, USA) and chronic myelogenous leukemia cells K562 were grown at 371C under 5% CO 2 in RPMI 1640 medium (Gibco BRL; Paisley, UK) supplemented with 5% FCS and 100 mg/ml penicillin/streptomycin. HeLa cells were grown at 371C under 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM, Gibco BRL) supplemented with 10% FCS and 100 mg/ml penicillin/streptomycin. The human B lymphoma cell line Ramos (EBVÀ) has been described elsewhere and was grown at 371C under 5% CO 2 in RPMI 1640 medium supplemented with 10% FCS, 50 mM b-mercaptoethanol and 100 mg/ml penicillin/streptomycin. Freshly prepared thymocytes from 12 weeks mice were plated in RPMI 1640 medium supplemented with 10% FCS at 4 or 371C under 5% CO 2 as previously described (Pages et al., 1999; Ricci et al., 2001) .
Western blot
Cells were incubated with different effectors for the times indicated in the figure legends, and then lysed in buffer B containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 20 mM EDTA, 100 mM NaF, 10 mM Na 3 VO 4 , 1 mM PMSF, 1 mM leupeptin, 20 mg/ml aprotinin, and 1% Triton X-100. A total of 100 mg of protein were separated on 10-12% polyacrylamide gel and transferred onto PVDF membrane (Immobilon-P, Millipore; Bedford, MA, USA). After blocking nonspecific binding sites, the membranes were incubated with specific antibodies. The membranes were washed three times with TNA-1 % NP-40 (Tris 50 mM, NaCl 150 mM, pH 7.5) incubated further with horseradish peroxidase conjugated antibody for 60 min at room temperature. Immunoblots were revealed by autoradiography using the enhanced chemiluminescence detection kit (Amersham Biosciences; Uppsala, Sweden).
DNA fragmentation
Thymocytes incubated at 4 or 371C for 4 h were lysed in 200 ml of lysis buffer containing 10 mM Tris (pH 7.5), 1 mM EDTA, and 0.2% Triton X-100. Samples were treated with 100 mg/ml RNase A for 30 min and then treated with 100 mg/ml proteinase K for 30 min at 371C as described previously (Herrant et al., 2002) . DNA was isopropanol-precipitated, airdried, resuspended in Tris-EDTA buffer and incubated for 30 min at 551C. DNA was analysed by electrophoresis on a 1.4% agarose gel containing ethidium bromide.
Caspase activity measurement
Each assay (in triplicate) was performed with 100 mg of protein prepared from thymocytes incubated at 4 or 371C for 4 h as described previously . Briefly, cellular extracts were incubated in a 96-well plate with 0.2 mM of Ac-DEVD-pNA as substrate for various times at 371C. Caspase activity was measured at 410 nm in the presence or absence of 1 mM of Ac-DEVD-CHO. The specific caspase activity was expressed in nmoles of paranitroaniline released per min and per mg of protein. Mutations and deletions were verified by sequencing. All these cDNAs were cloned into a pcDNA3 myc-his vector (Invitrogen ; Cergy Pontoise, France).
Generation of uncleavable or deleted Mcl-1 forms
In vitro transcription and translation of Mcl-1
Wild-type, mutated and deleted Mcl-1 constructs were transcribed and translated by using the Promega (Madison, WI, USA) TNT coupled reticulocyte lysate system in the presence of 35 S-methionine (ICN Biomedicals; Irvine, CA, USA) as previously described (Bertolotto et al., 2000) . Briefly, 2.5 ml of reticulocyte lysates were incubated in 50 ml of 25 mM HEPES pH 7.5, 0.1% CHAPS, 5 mM DTT with 25 ng recombinant caspases 3, 6 or 7 (BD PharMingen; San Diego, CA, USA) or 100 mg of Fas-stimulated Jurkat T cell extracts for 8 h at 371C. In some experiments, the effect of a caspase inhibitor (Ac-DEVD-CHO, 10 mM) was also monitored. Proteins contained in cell lysates were electrophoresed on 10% polyacrylamide gels. Gels were autoradiographed using Amersham hyperfilm.
Transfection and cleavage of Mcl-1 mutants in HeLa cells
Myc-tagged wild-type, double-mutated and deleted Mcl-1 constructs were transiently transfected in HeLa cells by using the phosphate Ca 2 þ procedure. After 48 h, cells were lysed in buffer B. In total, 100 mg of proteins were incubated or not with 100 ng of purified recombinant caspase 3 for 15 h at 371C. Proteins were electrophoresed on a 10% polyacrylamide gel and transferred onto a PVDF membrane. Wild-type, doublemutated and deleted Mcl-1 proteins were detected by using anti-Mcl-1 or anti-Myc antibodies.
Confocal microscopy
Wild-type and D127 Mcl-1 constructs and/or EGFP-Bim-EL were transiently transfected in HeLa cells by using the phosphate Ca 2 þ procedure. After 48 h, cells were fixed in 3.7% formaldehyde for 20 min at room temperature and permeabilized with 0.2% Triton X-100 for 5 min. Permeabilized cells were incubated with anti-Mcl-1, anti-a-Tubulin or anti-Hexokinase-2 (mitochondria) antibodies for 1 h at room temperature. After three washes with PBS, cells were incubated with the appropriate fluorescent-conjugated secondary antibodies. Cells were then washed three times with PBS and mounted on glass slides in Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL, USA). Slides were finally examined and photographed with a confocal microscope (Leica).
Immunoprecipitation experiments
Myc-tagged wild-type, double-mutated or D127 Mcl-1 and EGFP-Bim-EL constructs were transiently transfected in HeLa cells by using the phosphate Ca 2 þ procedure. After 48 h, cells were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 20 mM EDTA, 50 mM NaF, 0.5% NP-40, 0.1 mM Na 3 VO 4 , 1 mM leupeptin, 20 mg/ml aprotinin, 1 mM dithiothreitol and 1 mM PMSF). Lysates (500 ml) were then incubated with 1.5 mg of anti-Bim antibody and 15 ml protein G Sepharose (Amersham Biosciences) at 41C overnight. Beads were next washed five times with 1 ml lysis buffer before boiling in Laemmli sample buffer and performing SDS-polyacrylamide gel electrophoresis, transfer onto nitrocellulose membrane and immunoblotting with the indicated antibodies.
Flow cytometry
HeLa cells were transiently transfected with wild-type, doublemutated, D127 Mcl-1 constructs or control vector (5 mg) and EGFP-Bim-EL (1 mg). After 24 h of expression, cells were stained using the Anti-active-caspase-3-PE MAb Apoptosis Kit (BD Biosciences; San Diego, CA, USA). Fluorescence was measured by using the FL1 channel of a FACScan (Becton Dickinson; Cowley, UK).
